SCHEMBL4313284

SCHEMBL4313284

Cc1cccnc1CNc1cc2c(=O)c3cc(-c4ccc(C(=O)N5CCOCC5)cc4)cnc3ccc2cn1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MET P08581 4/20 0.44
MKNK1 Q9BUB5 2/20 0.42
MKNK2 Q9HBH9 2/20 0.42
RIPK1 Q13546 1/20 0.42
ABL1 P00519 1/20 0.41
MAPK10 P53779 1/20 0.40
HPGD P15428 2/20 0.40
CSF1R P07333 1/20 0.38
CCNT1 O60563 2/20 0.38
CDK9 P50750 2/20 0.38
SRC P12931 1/20 0.38
BDKRB1 P46663 1/20 0.38
KDM4E B2RXH2 1/20 0.38
RAB9A P51151 1/20 0.38
MST1R Q04912 1/20 0.37
CCNC P24863 1/20 0.37
CDK8 P49336 1/20 0.37
GRIN2B Q13224 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4308766 0.92 MTOR (0.43) METRIPK1HPGDCCNT1CDK9
SCHEMBL5067593 0.81 MET (0.39) METMST1R
SCHEMBL4308952 0.80 MET (0.57) METMST1R
SCHEMBL13859978 0.78 PDE10A (0.40) METMST1R
SCHEMBL4312490 0.76 MET (0.45) METMST1R
SCHEMBL4307810 0.75 MET (0.57) METMST1R
SCHEMBL2449126 0.74 MET (0.47) METMAPK10
SCHEMBL2445891 0.72 MET (0.49) METMAPK10MST1R
SCHEMBL2451460 0.72 MET (0.45) METMST1R
SCHEMBL2443780 0.71 CCND3 (0.43) METCDK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090131423-A1 Tyrosine Kinase Inhibitors MERCK & CO., INC. (US) 2009-05-21 US claimed
US-20090131423-A1 Tyrosine Kinase Inhibitors MERCK & CO., INC. (US) 2009-05-21 US disclosed
US-20090131423-A1 Tyrosine Kinase Inhibitors MERCK & CO., INC. (US) 2009-05-21 US disclosed
US-20090131423-A1 Tyrosine Kinase Inhibitors MERCK & CO., INC. (US) 2009-05-21 US disclosed
WO-2007050383-A2 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2007-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131423-A1 Tyrosine Kinase Inhibitors ABL1, ERBB2, MET MET 3/4885MKNK1 146/4885MKNK2 145/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.